Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Gene patenting policies affect patient access to testing for disease-causing genes: Study

Policies allowing genes to be patented can make it more difficult for patients to access testing for important disease-causing gene mutations, according to a series of papers in a special online supplement published by Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.

7 May 2010

Two-day symposium on molecular neuroimaging

Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplines-including chemistry, engineering, physics, molecular biology, neurosciences and imaging sciences-to promote the emerging field of molecular neuroimaging.

7 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

Peptides: A new clue on the origins of life

Emory University scientists have discovered that simple peptides can organize into bi-layer membranes. The finding suggests a "missing link" between the pre-biotic Earth's chemical inventory and the organizational scaffolding essential to life.

7 May 2010

54% of liver cirrhosis patients experience neurocognitive impairments

More than half of patients who have cirrhosis of the liver also display neurocognitive impairments such as short term memory loss, a study led by a Loyola University Health System researcher has found.

7 May 2010

Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.

7 May 2010

Intellect Neurosciences signs debt settlement agreement with CARBOGEN AMCIS AG

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.

6 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

GENFIT announces milestone as compound developed in partnership enters the clinic

GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the achievement of a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners.

6 May 2010

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

Researchers at Johns Hopkins have discovered that a compound in dark chocolate may protect the brain after a stroke by increasing cellular signals already known to shield nerve cells from damage.

6 May 2010

Scientists use specialized fluorescent protein to study nerve cell activity

Electrical currents are invisible to the naked eye - at least they are when they flow through metal cables. In nerve cells, however, scientists are able to make electrical signals visible. Working with fellow experts from Switzerland and Japan, scientists from the Max Planck Institute for Medical Research in Heidelberg successfully used a specialized fluorescent protein to visualize electrical activity in neurons of living mice.

6 May 2010

Spouses of dementia sufferers at higher risk of developing dementia

Older married adults whose spouse has dementia are at significantly higher risk for developing dementia themselves, compared to similar older married adults whose spouse never develops dementia. This is the key finding of a study published today in the Journal of the American Geriatrics Society.

5 May 2010

Principals of StemTroniX, Power3 Medical Products file patent application

StemTroniX, Inc., a Texas corporation, and Power3 Medical Products, Inc. announced today that a joint provisional patent application entitled, "Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy" has been filed by the principals of StemTroniX and Power3 with the United States Patent and Trademark Office.

5 May 2010

Older adults with depression do not respond to emotional stimuli, says study

Scientists have found an important clue in the quest to understand why people who suffer from depression in later life are harder to treat and keep well in the long term.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

Research analyzes clinical connection of NPH to AD

Normal Pressure Hydrocephalus is a neurological condition which typically affects adults ages 55 and older. This condition was first described in the 1960s as a triad of gait disturbance, dementia, and bladder incontinence. The ventricles of the brain appear enlarged although the cerebrospinal fluid pressure remains normal.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Living with a dementia sufferer may affect spouse

In a new study researchers have revealed that partners of patients suffering from dementia or degeneration of memory and other mental faculties are six times more likely to develop the condition themselves.

4 May 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases such as Alzheimer's disease (AD), announced today the detection of the AD-associated aggregated Beta-amyloid (ABeta), the hallmark of AD, in the blood from the most-frequently-used animal model of AD. The assay detects both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD.

4 May 2010

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Gene patenting policies affect patient access to testing for disease-causing genes: Study

Two-day symposium on molecular neuroimaging

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Peptides: A new clue on the origins of life

54% of liver cirrhosis patients experience neurocognitive impairments

Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

Intellect Neurosciences signs debt settlement agreement with CARBOGEN AMCIS AG

RayBiotech announces biomarker grant winners

GENFIT announces milestone as compound developed in partnership enters the clinic

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

Scientists use specialized fluorescent protein to study nerve cell activity

Spouses of dementia sufferers at higher risk of developing dementia

Principals of StemTroniX, Power3 Medical Products file patent application

Older adults with depression do not respond to emotional stimuli, says study

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Research analyzes clinical connection of NPH to AD

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Living with a dementia sufferer may affect spouse

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in